-transparent.png){kind=logo}
Future studies with daunorubicin involve mainly comparative evaluations with other anthracycline antibiotics and related compounds. Efforts are ongoing to improve the therapeutic index of these drugs. This includes not only laboratory development but also clinical evaluation of analogs, manipulations in dose schedules, and the use of protectors of toxic manifestations, primarily of cardiomyopathy. Technological advances in the clinical area permit, for example, the exploration of daunorubicin and related compounds by continuous infusion under more precise pharmacologic and cardiologic monitoring than was possible when they were initially introduced.
Related Publications
F M Muggia, and
R H Blum, and
J C Wernz
May 1984,
Biochimie,
F M Muggia, and
R H Blum, and
J C Wernz
August 2001,
Electrophoresis,
F M Muggia, and
R H Blum, and
J C Wernz
April 1988,
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
F M Muggia, and
R H Blum, and
J C Wernz
November 2009,
Advanced drug delivery reviews,
F M Muggia, and
R H Blum, and
J C Wernz
December 1992,
The Journal of antibiotics,
F M Muggia, and
R H Blum, and
J C Wernz
December 1977,
The Japanese journal of antibiotics,
F M Muggia, and
R H Blum, and
J C Wernz
October 1984,
Cancer letters,
F M Muggia, and
R H Blum, and
J C Wernz
February 1985,
Biochemical pharmacology,
F M Muggia, and
R H Blum, and
J C Wernz
April 1988,
Behring Institute Mitteilungen,
F M Muggia, and
R H Blum, and
J C Wernz
January 1986,
Progress in clinical and biological research,
